– USA, MA – Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of industry veteran Thomas Wiggans to its board of directors.
Mr. Wiggans has led successful biopharmaceutical companies from the start-up stage into the clinic and later global commercialization served on the boards of numerous public and private companies and was instrumental in the formation of the Biotechnology Industry Organization, now Biotechnology Innovation Organization.
“I am delighted to welcome Tom to our board,” said Board Chair, Peter Wirth. “Tom’s distinguished career as a leader of biopharma companies, as well as an entrepreneur, will serve as a critical resource to Forma.”
“Tom brings decades of experience leading the development and commercialization of new therapeutics,” said CEO, Frank Lee. “We look forward to leveraging his expertise to execute on our corporate and clinical strategies on behalf of the sickle cell community and those affected by prostate cancer.”
About Tom Wiggans
Mr. Wiggans is a veteran biopharmaceutical executive, having founded Dermira (NASDAQ: DERM) in 2010 and served as its chairman and CEO until it was acquired by Eli Lilly and Company in February 2020. Prior to founding Dermira, Mr. Wiggans served as chairman and CEO of Peplin, Inc. until Peplin’s acquisition by LEO Pharma A/S in 2009. He also served as chairman of the board of directors and CEO of Connetics Corporation until it was acquired by Stiefel Laboratories, Inc. in 2006. Prior to Connetics, he served as president and CEO of CytoTherapeutics Inc. and in various management positions at Ares-Serono S.A., including as president of its U.S. pharmaceutical operations and managing director of its U.K. pharmaceutical operations. He began his career with Eli Lilly and Company.
“I am excited to join Forma’s board at such a pivotal moment in the company’s growth,” said Tom Wiggans. “I look forward to working with the executive team and other accomplished board members to contribute to the company’s mission of bringing transformative medicines to patients with rare hematologic diseases and cancers.”
Mr. Wiggans has served on the boards of numerous public and private companies including Excaliard, Somaxon, Corthera, Sangamo and Onyx. He is a long-standing member of the board of directors of BIO, as well as a member of the board of trustees of the University of Kansas Endowment Association. He holds a B.S. in pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet needs. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit.
For more information: https://www.formatherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
